Pacira Pharmaceuticals Inc (PCRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Pacira Pharmaceuticals Inc (PCRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9853
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Pacira Pharmaceuticals Inc (Pacira) discovers, develops, manufactures and commercializes drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. Its other products developed under partnerships include DepoCyt (cytarabine liposome injection) for lymphomatous meningitis; and Nocita (bupivacaine liposome injectable suspension) for surgical infiltration in dogs. Its products are used by hospitals and ambulatory surgery centers. The company sells its products through co-promotion agreements and supply agreements with other pharma companies. Pacira is headquartered in Parsippany, New Jersey, the US.

Pacira Pharmaceuticals Inc (PCRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Pacira Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 11
Licensing Agreements 12
Nuance Biotech Enters into Licensing Agreement with Pacira Pharma 12
Pacira Pharma Enters into Licensing Agreement with Aratana Therapeutics 13
Equity Offering 15
Pacira Pharma Completes Public Offering Of Shares For US$117.8 Million 15
Pacira Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$67 Million 17
Debt Offering 19
Pacira Pharma Raises USD345 Million in Private Placement of Notes Due 2022 19
Pacira Pharma Completes Private Placement Of Notes Due 2019 For US$120 Million 21
Pacira Pharmaceuticals Inc – Key Competitors 22
Pacira Pharmaceuticals Inc – Key Employees 23
Pacira Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 01, 2018: Pacira Pharmaceuticalsb reports third quarter 2018 financial results 25
Aug 02, 2018: Pacira Pharmaceuticals reports second quarter 2018 financial results 26
May 03, 2018: Pacira Pharmaceuticals Reports First Quarter 2018 Financial Results 27
Feb 28, 2018: Pacira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 28
Nov 11, 2017: Pacira Pharmaceuticals Reports Third Quarter 2017 Financial Results 30
Mar 01, 2017: Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update 31
Jan 06, 2017: Pacira Pharmaceuticals Reports Preliminary 2016 Revenues of $276.4 Million 32
Corporate Communications 33
Jun 15, 2017: Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors 33
May 23, 2017: Pacira Pharmaceuticals Announces Resignation of James Scibetta 34
Other Significant Developments 35
Jul 10, 2018: Pacira Reports Preliminary Net EXPAREL Sales of $80.4 Million for Second Quarter of 2018 35
Jun 13, 2018: MEDNAX National Medical Group and Pacira Pharmaceuticals Launch National Enhanced Recovery after Cesarean Surgery (ERACS) Collaborative to Minimize Opioid Use 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pacira Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Pacira Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 11
Nuance Biotech Enters into Licensing Agreement with Pacira Pharma 12
Pacira Pharma Enters into Licensing Agreement with Aratana Therapeutics 13
Pacira Pharma Completes Public Offering Of Shares For US$117.8 Million 15
Pacira Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$67 Million 17
Pacira Pharma Raises USD345 Million in Private Placement of Notes Due 2022 19
Pacira Pharma Completes Private Placement Of Notes Due 2019 For US$120 Million 21
Pacira Pharmaceuticals Inc, Key Competitors 22
Pacira Pharmaceuticals Inc, Key Employees 23
Pacira Pharmaceuticals Inc, Other Locations 24
Pacira Pharmaceuticals Inc, Subsidiaries 24

List of Figures
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pacira Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Pacira Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Pacira Pharmaceuticals Inc (PCRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • LA DORIA S.p.A.:企業の戦略・SWOT・財務情報
    LA DORIA S.p.A. - Strategy, SWOT and Corporate Finance Report Summary LA DORIA S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Vanguard Natural Resources Inc (VNRR):石油・ガス:M&Aディール及び事業提携情報
    Summary Vanguard Natural Resources, Inc (Vanguard) is an independent oil and gas company with upstream operations. It acquires, produces, and develops oil and natural gas properties. The company owns producing and non-producing oil and natural gas assets in the Green River Basin in Wyoming; the Perm …
  • Legend Mining Ltd:企業の戦略・SWOT・財務情報
    Legend Mining Ltd - Strategy, SWOT and Corporate Finance Report Summary Legend Mining Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Seair Inc:企業の戦略的SWOT分析
    Seair Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • OKD as:企業の戦略・SWOT・財務情報
    OKD as - Strategy, SWOT and Corporate Finance Report Summary OKD as - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • MannKind Corp (MNKD):製薬・医療:M&Aディール及び事業提携情報
    Summary MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a US FDA approved rapid-action inhaled insulin used to control high …
  • Zai Lab Ltd (ZLAB):製薬・医療:M&Aディール及び事業提携情報
    Summary Zai Lab Ltd (Zai Lab) is a biopharmaceutical company that discovers, develops and manufactures transformative medicines for cancer, autoimmune and infectious diseases. The company’s pipeline products include ZL-2306, ZL-2401, FPA144, EXT2514SUL, ZL-2301, ZL-3101, ZL-2302 and ZL-1101. It deve …
  • Medivir AB (MVIR B):企業の財務・戦略的SWOT分析
    Summary Medivir AB (Medivir) is a pharmaceutical company. It is engaged in drug discovery and development of treatments for cancer.The company offers products under development for the treatment of cutaneous T-cell lymphoma, osteoarthritis, solid tumors, hepatocellular carcinoma and acute myeloid le …
  • Hurricane Energy plc (HUR):企業の財務・戦略的SWOT分析
    Summary Hurricane Energy Plc (Hurricane) is an oil and gas exploration and development company that discovers and develops oil from fractured basement reservoirs. The company provides exploration properties such as lancaster basement prospect, whirlwind basement discovery, lincoln basement prospect, …
  • Interstate Hotels & Resorts Inc:戦略・SWOT・企業財務分析
    Interstate Hotels & Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Interstate Hotels & Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Synedgen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Synedgen Inc (Synedgen) is a biotechnology company that focuses on the discovery and development of polysaccharide-based drugs. The company’s pipeline products include SYGN 113; SYGN 115; SYGN 146; SYGN 303; SYGN 313 and SYGN 399 among others. Synedgen develops products for the treatment of …
  • Nippon Yusen Kabushiki Kaisha (9101)-石油・ガス分野:企業M&A・提携分析
    Summary Nippon Yusen Kabushiki Kaisha (NYK) is a logistics company transporting crude oil and allied products. The company provides ocean, land, and air transport services for the transportation of petroleum products, liquid products and dry bulk products. Its portfolio includes line trade, air carg …
  • Stanbic Ibtc Holdings Plc
    Stanbic Ibtc Holdings Plc - Strategy, SWOT and Corporate Finance Report Summary Stanbic Ibtc Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • SolarEdge Technologies Inc (SEDG):電力:M&Aディール及び事業提携情報
    Summary SolarEdge Technologies Inc (SolarEdge) is a provider of intelligent inverter solutions for the photovoltaic (PV) industry. The company provides module-level power electronics for solar power harvesting and monitoring. Its system consists of inverters, power optimizers, storage solutions, and …
  • Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ):製薬・医療:M&Aディール及び事業提携情報
    Summary Eckert & Ziegler Strahlen- und Medizintechnik AG (Eckert & Ziegler) is a medical device company that offers isotope technology products. The company offers radiation therapy, isotope and radio-pharma products. It provides radiation therapy products for Brachytherapy, a minimally invasive pro …
  • Andersen Construction Company:企業の戦略的SWOT分析
    Andersen Construction Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Po Valley Energy Ltd (PVE):企業の財務・戦略的SWOT分析
    Summary Po Valley Energy Ltd (Po Valley Energy) is an oil and gas company that offers exploration and development of hydrocarbon assets. The company's projects include Sillaro, Castello or Bezzecca, Sant'Alberto, Teodorico and Selva. Its Sillaro field is located in the province of Bologna with seven …
  • REC Silicon ASA (REC)-エネルギー分野:企業M&A・提携分析
    Summary REC Silicon ASA (REC Silicon), formerly Renewable Energy Corporation ASA, produces and supplies advanced silicon materials. It offers solar grade polysilicon, electronic grade polysilicon, and silicon gases. Its products find application in the solar and electronics industries in the product …
  • icapital biz Berhad:企業の戦略・SWOT・財務情報
    icapital biz Berhad - Strategy, SWOT and Corporate Finance Report Summary icapital biz Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Inter RAO UES (IRAO):企業の財務・戦略的SWOT分析
    Inter RAO UES (IRAO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆